Previous 10 | Next 10 |
2023-05-19 12:34:48 ET Adamis Pharmaceuticals ( NASDAQ: ADMP ) fell ~19% on Friday after announcing plans to effect a 1-for-70 reverse stock split of its common stock from next week. Accordingly, the reverse stock split will take effect on May 22, 2023, at 12:01 a.m., and ...
SAN DIEGO, May 19, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, announced today that it will effect a 1-for-70 reverse stock split of its common stock that will become effective on May 22, 2023, at 12:01 a.m., Easter...
2023-05-15 18:32:06 ET Adamis Pharmaceuticals Corporation (ADMP) Q1 2023 Earnings Conference Call May 15, 2023, 05:00 PM ET Company Participants Robert Uhl - MD, ICR Westwicke David Marguglio - CEO David Benedicto - CFO Eboo Versi - CEO, DMK Pharmaceuticals ...
2023-05-15 16:51:04 ET Adamis Pharmaceuticals press release ( NASDAQ: ADMP ): Q1 GAAP EPS of -$0.06. Revenue of $1.45M (+20.8% Y/Y). For further details see: Adamis Pharmaceuticals GAAP EPS of -$0.06, revenue of $1.45M
SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease...
2023-05-12 10:44:38 ET Major earnings expected before the bell on Monday include: Adamis Pharmaceuticals ( ADMP ) CV Sciences ( OTCQB:CVSI ) Sundial Growers ( SNDL ) Sunworks ( SUNW ) Workhorse Group ( WKHS ) For further details see: Notab...
SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammato...
2023-03-17 16:50:24 ET Adamis Pharmaceuticals Corporation (ADMP) Q4 2022 Results Conference Call March 16, 2023 05:00 PM ET Company Participants Robert Uhl - MD, ICR Westwicke David Marguglio - CEO David Benedicto - CFO Dr. Eboo Versi - CEO, DMK Pharmaceutica...
2023-03-16 16:32:25 ET Adamis Pharmaceuticals press release ( NASDAQ: ADMP ): FY GAAP EPS of -$0.18. Revenue of $4.75M (+115.9% Y/Y). For further details see: Adamis Pharmaceuticals GAAP EPS of -$0.18, revenue of $4.75M
SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announc...
News, Short Squeeze, Breakout and More Instantly...
Adamis Pharmaceuticals Corporation Company Name:
ADMP Stock Symbol:
NASDAQ Market:
Adamis Pharmaceuticals Corporation Website:
SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the company changed its name to DMK Pharmaceuticals Corporation in order to better reflect its new strategic focus on advancing sm...
SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments. Q2 2023 ...
SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock (or pre-funded warrant in...